Skip to main content
KOMIPHARM INTERNATIONAL CO., LTD. logo

KOMIPHARM INTERNATIONAL CO., LTD. — Investor Relations & Filings

Ticker · 041960 ISIN · KR7041960006 KO Manufacturing
Open in API
Filings indexed 326 across all filing types
Latest filing 2020-11-16 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 041960

About KOMIPHARM INTERNATIONAL CO., LTD.

https://komipharm.co.kr/en/

Komipharm International Co., Ltd. is a biopharmaceutical company engaged in the development, manufacturing, and sale of products for both animal and human health. Its Animal Health Division provides a portfolio of veterinary vaccines, pharmaceuticals, and disinfectants. The company's Pharmaceutical Division is dedicated to the research and development of novel therapeutic agents, with key research areas including anticancer drugs and treatments for cancer-related pain and autoimmune diseases. Leveraging extensive experience, the company focuses on intensive R&D to expand its presence in the global bio-industry.

Recent filings

Filing Released Lang Actions
분기보고서 (2020.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Komipharm, covering the period from January 1, 2020, to September 30, 2020. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-16 Korean
투자판단관련주요경영사항(코로나-19 바이러스로 인한 폐렴환자에서 PAX-1의 안전성 및 유효성 평가를 위한 스페인의약품위생제품청(AEMPS) 임상2/3상 임상시험계획 신청 거절)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory disclosure from a Korean company (KomiPharm) regarding the rejection of a clinical trial application by the Spanish Agency of Medicines and Medical Devices (AEMPS). It is a formal announcement of a material event concerning the company's business operations and regulatory status. Since it does not fit into specific categories like financial reports, dividends, or share transactions, and is a formal regulatory disclosure filed with the exchange, it is classified as a Regulatory Filing (RNS).
2020-10-14 Korean
투자판단관련주요경영사항(지속적인 암 통증 환자에서 PAX-1의 진통 활동을 평가하기 위한 탐색적, 무작위, 이중 맹검, 병렬 그룹, 위약 대조 Ⅱa상에 대한 대만식약청(TFDA) 임상시험계획 신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from a Korean company (Komipharm) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the application for a Phase IIa clinical trial with the Taiwan Food and Drug Administration (TFDA). This type of disclosure is a standard regulatory announcement for material corporate events in the Korean market. Since it does not fit into specific categories like M&A, dividends, or financial reports, it falls under the 'Regulatory Filings' category.
2020-10-13 Korean
투자판단관련주요경영사항(교모세포종 및 재발성 교모세포종 환자에서 PAX-1의 안전성 및 유효성 평가를 위한 식품의약품안전처(MFDS) 임상 2상 임상시험계획승인(IND) 신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Major Management Matter' disclosure regarding a clinical trial application (IND) for a Phase 2 study of PAX-1. Since this is a specific regulatory announcement of a material event (clinical trial application) that does not fit into categories like financial reports, dividends, or shareholder meetings, it falls under the 'Regulatory Filings' (RNS) category.
2020-09-18 Korean
투자판단관련주요경영사항(코로나-19 바이러스로 인한 폐렴환자에서 PAX-1의 안전성 유효성 평가를 위한 이탈리아의약품청(AIFA) 임상2/3상 임상시험계획 신청 자진 취하 통보)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the voluntary withdrawal of a clinical trial application (PAX-1 for COVID-19) in Italy. Since this is a specific regulatory disclosure regarding clinical trial status and business operations that does not fit into categories like financial reports, dividends, or M&A, it is classified as a general regulatory filing.
2020-09-08 Korean
반기보고서 (2020.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company '코미팜' (Komipharm) for the period ending June 30, 2020. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2020
2020-08-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.